Upgrade: Analysts Just Made A Substantial Increase To Their Hyloris Pharmaceuticals SA (EBR:HYL) Forecasts
Jun 26
Have your own idea? Try our Stock Screener
Belgian (BEL20) Pharma Industry Analysis
UpdatedJul 14, 2025
DataAggregated Company Financials
Companies3
- 7D0.6%
- 3M19.8%
- 1Y18.4%
- YTDn/a
In the last week, the Pharma industry is up 1.3%, with UCB up 1.2%. This takes the industry's 12 month performance to a gain of 19%. Earnings are forecast to grow by 18% annually.
Industry Valuation and Performance
Has the Belgian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 14 Jul 2025 | €38.7b | €6.2b | €1.1b | 48.8x | 33.7x | 6.3x |
| Wed, 11 Jun 2025 | €37.3b | €6.2b | €1.1b | 46.8x | 32.4x | 6x |
| Fri, 09 May 2025 | €34.3b | €6.2b | €1.1b | 43.2x | 29.9x | 5.6x |
| Sun, 06 Apr 2025 | €34.0b | €6.2b | €1.1b | 42.2x | 29.6x | 5.5x |
| Tue, 04 Mar 2025 | €43.3b | €6.2b | €1.1b | 54.1x | 38x | 7x |
| Thu, 30 Jan 2025 | €43.2b | €5.5b | €316.8m | 113.5x | 136.3x | 7.9x |
| Sat, 28 Dec 2024 | €43.1b | €5.5b | €316.8m | 111.6x | 136.1x | 7.9x |
| Mon, 25 Nov 2024 | €40.4b | €5.5b | €316.8m | 104.8x | 127.4x | 7.4x |
| Wed, 23 Oct 2024 | €38.8b | €5.5b | €316.8m | 102.1x | 122.6x | 7.1x |
| Fri, 20 Sep 2024 | €36.3b | €5.5b | €314.6m | 95.4x | 115.4x | 6.7x |
| Sun, 18 Aug 2024 | €34.3b | €5.5b | €314.6m | 88.4x | 109.1x | 6.3x |
| Tue, 16 Jul 2024 | €32.7b | €5.2b | €415.4m | 68.4x | 78.7x | 6.3x |
| Thu, 13 Jun 2024 | €29.9b | €5.2b | €415.4m | 64.7x | 71.9x | 5.8x |
| Sat, 11 May 2024 | €27.9b | €5.2b | €415.4m | 58.2x | 67.2x | 5.4x |
| Mon, 08 Apr 2024 | €26.1b | €5.2b | €415.4m | 54.8x | 62.9x | 5x |
| Wed, 06 Mar 2024 | €24.3b | €5.2b | €415.7m | 51.4x | 58.5x | 4.7x |
| Fri, 02 Feb 2024 | €20.2b | €5.1b | €404.7m | 44.5x | 49.9x | 4x |
| Sun, 31 Dec 2023 | €18.5b | €5.1b | €404.7m | 41.3x | 45.8x | 3.6x |
| Tue, 28 Nov 2023 | €16.4b | €5.1b | €408.5m | 36.3x | 40.1x | 3.2x |
| Thu, 26 Oct 2023 | €17.0b | €5.1b | €408.5m | 37.1x | 41.6x | 3.3x |
| Sat, 23 Sep 2023 | €19.2b | €5.2b | €348.9m | 41.1x | 55x | 3.7x |
| Mon, 21 Aug 2023 | €18.8b | €5.2b | €350.6m | 40.4x | 53.7x | 3.6x |
| Wed, 19 Jul 2023 | €18.9b | €5.5b | €434.8m | 36.8x | 43.4x | 3.4x |
| Fri, 16 Jun 2023 | €19.9b | €5.5b | €434.8m | 38.6x | 45.7x | 3.6x |
| Sun, 14 May 2023 | €20.0b | €5.5b | €434.8m | 39.1x | 46.1x | 3.6x |
| Tue, 11 Apr 2023 | €20.3b | €5.5b | €669.3m | 24.9x | 30.3x | 3.7x |
| Thu, 09 Mar 2023 | €19.2b | €5.5b | €634.9m | 23.5x | 30.2x | 3.5x |
| Sat, 04 Feb 2023 | €18.1b | €5.9b | €1.1b | 13.2x | 16.4x | 3.1x |
| Mon, 02 Jan 2023 | €17.6b | €5.9b | €1.1b | 12.8x | 16x | 3x |
| Wed, 30 Nov 2022 | €18.4b | €5.9b | €1.1b | 13.2x | 16.7x | 3.1x |
| Fri, 28 Oct 2022 | €17.7b | €5.9b | €1.1b | 12.6x | 16.1x | 3x |
| Sun, 25 Sep 2022 | €16.9b | €5.9b | €1.1b | 12.2x | 15.7x | 2.9x |
| Tue, 23 Aug 2022 | €17.7b | €5.9b | €1.1b | 12.8x | 16.4x | 3x |
| Thu, 21 Jul 2022 | €19.9b | €5.8b | €1.3b | 11.9x | 15.2x | 3.4x |
Price to Earnings Ratio
15.2x
Current Industry PE
- There are only 3 companies in the Belgian Pharmaceuticals industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have declined 4.2% per year over the last three years.
- Meanwhile revenues for these companies have grown 2.0% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does Belgian Pharma compare with similar industries?
| BE Market | -0.16% | |
| Healthcare | 1.60% | |
| Pharma | 0.61% | |
| Pharma | 0.61% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| UCB UCB | €172.55 | 1.6% +€503.6m | 20.0% | PE30.8x | |
| TUB Financière de Tubize | €136.40 | 0.9% +€53.4m | 20.3% | PE67.4x | |
| HYL Hyloris Pharmaceuticals | €6.30 | 0.3% +€560.0k | -46.2% | PS18.1x |